膀胱癌患者机器人辅助与腹腔镜根治性膀胱切除术的围手术期和肿瘤预后。

IF 1.6 4区 医学 Q4 ONCOLOGY
Noriya Yamaguchi, Shuichi Morizane, Hiroshi Yamane, Ryutaro Shimizu, Ryoma Nishikawa, Yusuke Kimura, Katsuya Hikita, Kuniyasu Muraoka, Hirofumi Ono, Koji Ono, Masashi Honda, Atsushi Takenaka
{"title":"膀胱癌患者机器人辅助与腹腔镜根治性膀胱切除术的围手术期和肿瘤预后。","authors":"Noriya Yamaguchi, Shuichi Morizane, Hiroshi Yamane, Ryutaro Shimizu, Ryoma Nishikawa, Yusuke Kimura, Katsuya Hikita, Kuniyasu Muraoka, Hirofumi Ono, Koji Ono, Masashi Honda, Atsushi Takenaka","doi":"10.21873/anticanres.17508","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Few studies have verified the relationship between treatment outcomes of robot-assisted radical cystectomy (RARC) and laparoscopic radical cystectomy (LRC). This study aimed to compare the perioperative and oncologic outcomes between RARC and LRC.</p><p><strong>Patients and methods: </strong>Medical records of 75 patients (45 RARC and 30 LRC) who underwent radical cystectomy and standard or higher lymph node dissection between April 2013 and December 2019 at the Tottori University and other satellite hospitals were reviewed.</p><p><strong>Results: </strong>The operative time was shorter in the LRC group. Mean estimated blood loss was lower in the RARC group. No differences were noted in the complication rates. The mean number of lymph nodes removed was 23.1 in the RARC group and 13.9 in the LRC group (<i>p</i><0.001). Cox proportional hazards regression analysis showed that the tumor variant of the transurethrally resected bladder tumor (TUR-BT) tissue (<i>p</i>=0.032) and lymph node metastasis (<i>p</i>= 0.041) were significantly associated with a higher risk of cancer-specific survival (CSS). No difference in the CSS (<i>p</i>= 0.337) and recurrence-free survival (<i>p</i>=0.448) was found in all patients having either RARC or LRC. However, the CSS of RARC was higher than that of LRC (<i>p</i>=0.032) in patients with locally advanced stages of bladder cancer such as pathological T stage ≥3 or pathological lymph node positivity.</p><p><strong>Conclusion: </strong>In patients with locally advanced bladder cancer pathological T stage ≥3 or pathological lymph node positivity, LRC appears to be associated with shorter CSS than RARC.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1215-1224"},"PeriodicalIF":1.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Perioperative and Oncologic Outcomes of Robot-assisted <i>Versus</i> Laparoscopic Radical Cystectomy in Patients With Bladder Cancer.\",\"authors\":\"Noriya Yamaguchi, Shuichi Morizane, Hiroshi Yamane, Ryutaro Shimizu, Ryoma Nishikawa, Yusuke Kimura, Katsuya Hikita, Kuniyasu Muraoka, Hirofumi Ono, Koji Ono, Masashi Honda, Atsushi Takenaka\",\"doi\":\"10.21873/anticanres.17508\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aim: </strong>Few studies have verified the relationship between treatment outcomes of robot-assisted radical cystectomy (RARC) and laparoscopic radical cystectomy (LRC). This study aimed to compare the perioperative and oncologic outcomes between RARC and LRC.</p><p><strong>Patients and methods: </strong>Medical records of 75 patients (45 RARC and 30 LRC) who underwent radical cystectomy and standard or higher lymph node dissection between April 2013 and December 2019 at the Tottori University and other satellite hospitals were reviewed.</p><p><strong>Results: </strong>The operative time was shorter in the LRC group. Mean estimated blood loss was lower in the RARC group. No differences were noted in the complication rates. The mean number of lymph nodes removed was 23.1 in the RARC group and 13.9 in the LRC group (<i>p</i><0.001). Cox proportional hazards regression analysis showed that the tumor variant of the transurethrally resected bladder tumor (TUR-BT) tissue (<i>p</i>=0.032) and lymph node metastasis (<i>p</i>= 0.041) were significantly associated with a higher risk of cancer-specific survival (CSS). No difference in the CSS (<i>p</i>= 0.337) and recurrence-free survival (<i>p</i>=0.448) was found in all patients having either RARC or LRC. However, the CSS of RARC was higher than that of LRC (<i>p</i>=0.032) in patients with locally advanced stages of bladder cancer such as pathological T stage ≥3 or pathological lymph node positivity.</p><p><strong>Conclusion: </strong>In patients with locally advanced bladder cancer pathological T stage ≥3 or pathological lymph node positivity, LRC appears to be associated with shorter CSS than RARC.</p>\",\"PeriodicalId\":8072,\"journal\":{\"name\":\"Anticancer research\",\"volume\":\"45 3\",\"pages\":\"1215-1224\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anticancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/anticanres.17508\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17508","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景/目的:很少有研究证实机器人辅助根治性膀胱切除术(RARC)与腹腔镜根治性膀胱切除术(LRC)治疗结果之间的关系。本研究旨在比较RARC和LRC的围手术期和肿瘤预后。患者和方法:回顾了2013年4月至2019年12月在鸟取大学和其他卫星医院接受根治性膀胱切除术和标准或更高级别淋巴结清扫的75例患者(45例RARC和30例LRC)的医疗记录。结果:LRC组手术时间明显缩短。RARC组的平均估计失血量较低。并发症发生率无明显差异。RARC组平均切除淋巴结数为23.1个,LRC组平均切除淋巴结数为13.9个(pp=0.032),淋巴结转移(p= 0.041)与较高的癌症特异性生存(CSS)风险显著相关。在所有RARC或LRC患者中,CSS (p= 0.337)和无复发生存率(p=0.448)均无差异。然而,在局部晚期膀胱癌如病理T期≥3或病理淋巴结阳性患者中,RARC的CSS高于LRC (p=0.032)。结论:在局部晚期膀胱癌病理T期≥3或病理淋巴结阳性患者中,LRC与较短的CSS相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Perioperative and Oncologic Outcomes of Robot-assisted Versus Laparoscopic Radical Cystectomy in Patients With Bladder Cancer.

Background/aim: Few studies have verified the relationship between treatment outcomes of robot-assisted radical cystectomy (RARC) and laparoscopic radical cystectomy (LRC). This study aimed to compare the perioperative and oncologic outcomes between RARC and LRC.

Patients and methods: Medical records of 75 patients (45 RARC and 30 LRC) who underwent radical cystectomy and standard or higher lymph node dissection between April 2013 and December 2019 at the Tottori University and other satellite hospitals were reviewed.

Results: The operative time was shorter in the LRC group. Mean estimated blood loss was lower in the RARC group. No differences were noted in the complication rates. The mean number of lymph nodes removed was 23.1 in the RARC group and 13.9 in the LRC group (p<0.001). Cox proportional hazards regression analysis showed that the tumor variant of the transurethrally resected bladder tumor (TUR-BT) tissue (p=0.032) and lymph node metastasis (p= 0.041) were significantly associated with a higher risk of cancer-specific survival (CSS). No difference in the CSS (p= 0.337) and recurrence-free survival (p=0.448) was found in all patients having either RARC or LRC. However, the CSS of RARC was higher than that of LRC (p=0.032) in patients with locally advanced stages of bladder cancer such as pathological T stage ≥3 or pathological lymph node positivity.

Conclusion: In patients with locally advanced bladder cancer pathological T stage ≥3 or pathological lymph node positivity, LRC appears to be associated with shorter CSS than RARC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Anticancer research
Anticancer research 医学-肿瘤学
CiteScore
3.70
自引率
10.00%
发文量
566
审稿时长
2 months
期刊介绍: ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信